| Amgen builds a blockbuster case for denosumab - FierceBiotech |
|
|
FierceBiotechThere is no need for renal monitoring or dose adjustments due to renal impairment," said David Henry of Pennsylvania Hospital, Philadelphia.Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in ... ReutersAmgen Says Denosumab Delayed Skeletal Related Events In Cancer ... read more |